Promotions & Moves

BeiGene Appoints CMO

Peterson to lead Immuno-oncology clinical development

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amy C. Peterson, M.D. has been appointed chief medical officer, Immuno-oncology at BeiGene, Ltd.  Dr. Peterson will lead the global clinical development of BGB-A317, BeiGene’s PD-1 inhibitor, and BGB-290, a PARP inhibitor, as well as its pipeline of other immuno-oncology agents. Dr. Eric Hedrick, currently serving as the interim chief medical officer, will continue to oversee global clinical hematology development including the program for BGB-3111, BeiGene’s BTK inhibitor, and will remain servi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters